Lenacapavir: a long-acting human immunodeficiency virus prevention strategy with the potential to transform global human immunodeficiency virus control

Abstract

Recent advancements in the prevention of HIV emphasize the need for newer strategies that can address the continuous gap in global HIV control. The incidence of HIV remains significantly high in certain populations, especially among young women, mobile communities, and individuals facing stigma-related barriers to care. While daily pre-exposure prophylaxis has been proven to be effective, limitations such as adherence to treatment and pill fatigue still pose challenges. Lenacapavir has been shown to be promising in this regard as a long-acting prevention modality that merits prompt consideration. Innovative approaches that are in line with real-world behavioral and structural challenges are an urgent requirement as the global community works to maintain the momentum of HIV elimination.